期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

原发性肺腺癌间质上皮转化因子mRNA的表达及意义 被引量：2

Expression and clinical significance of c-MET m RNA in primary lung adenocarcinoma: An analysis of 83 cases
下载PDF
导出
摘要 目的探讨间质上皮转化因子(mesenchymal-epithelial transition factor,c-MET)m RNA在原发性肺腺癌组织中的表达及意义。方法回顾性分析2011年7月-2013年10月在我院手术并确诊的83例原发性肺腺癌患者的临床资料及c-MET m RNA检测结果。根据c-MET m RNA检测结果将患者分为高表达组和低表达组。结果 83例中,c-MET m RNA高表达占36.1%(30/83)。高表达组淋巴结转移率为46.7%(14/30),高于低表达组的20.8%(11/53)(P<0.05)。高表达组临床分期Ⅰ、Ⅱ、Ⅲ期分别为53.3%(16/30)、30.0%(9/30)、16.7%(5/30),低表达组为75.5%(40/53)、17.0%(9/53)、7.5%(4/53),两组有统计学差异(P<0.05)。高表达组的1年、2年无进展生存率为53.3%和22.2%,低表达组为81.1%和67.9%,两组无进展生存时间有统计学差异(P<0.05)。多因素分析显示,c-MET m RNA表达水平(HR=2.298,P=0.019)、分化程度(HR=2.632,P=0.003)和临床分期(HR=3.048,P=0.019)是肺腺癌预后的独立危险因素。结论 c-MET m RNA过度表达可能是原发性肺腺癌患者预后不良的因素。 Objective To investigate the expression and clinical significance of c-MET mRNA in primary lung adenocarcinoma. Methods Clinical data and c-MET mRNA test results about 83 patients with primary lung adenocarcinoma who underwent surgery in our hospital from July 2011 to October 2013 were retrospectively analyzed. Patients were divided into c-MET mRNA overexpression group and low expression group. Results In 83 patients, the constituent ratio of overexpression group was 36.1% （30/83）. The lymph node metastasis rate of overexpression group and low expression group were 46.7% （14/30） and 20.8% （11/53） with significant difference （P 〈 0.05）. The I , 11 , 11I TNM stage of overexpression group and low expression group were 53.3% （16/30）, 30.0% （9/30）, 16.7% （5/30） and 75.5% （40/53）, 17.0% （9/53）, 7.5% （4/53）, which also showed significant differences （P 〈 0.05）. The 1-, 2-year progression-free survival rate of overexpression group and low expression group were 53.3%, 22.2% and 81.1%, 67.9% with significant difference （P 〈 0.05）. The multivariate analysis showed that c-MET mRNA level （HR=2.298, P=0.019）, differentiation （HR=2.632, P=0.003） and TNM stage （HR=3.048, P=0.019） were independent risk factors for prognosis. Conclusion c-MET mRNA overexpression is a negative prognostic factor for patients with primary lung adenocarcinoma.
作者 王辉 初向阳 王波 马克峰
机构地区 解放军总医院胸外科
出处 《解放军医学院学报》 CAS 2015年第7期661-663,667,共4页 Academic Journal of Chinese PLA Medical School
关键词 非小细胞肺癌 腺癌 间质上皮转化因子基因 non-small cell lung cancer adenocarcinoma mesenchymal-epithelial transition factor gene
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献4

二级参考文献76

  • 1岳东升,王长利.肺癌引流区淋巴结免疫状况[J].中国肿瘤临床,2007,34(3):177-180. 被引量：1
  • 2Jema A, Bray F, Center MM, et al. Global Cancer Statistics. CA Cancer J Clin, 2011, 61(2): 69-90.
  • 3Stein U, Walther W, Arlt F, et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nature Med, 2009, 15(1): 59-67.
  • 4Shirahata A, Sakata M, Kitamura Y, et al. MACC1 as a marker for peritoneal-disseminated gastric carcinoma. Anticancer Res, 2010, 30( 9): 3441-3444.
  • 5Shirahata A, Fan W, Sakuraba K, et al. MACC1 as a marker for vascular invasive hepatocellular carcinoma. Anticancer Res, 2011, 31 (3): 777 -7S0.
  • 6QjuJ, Huang P, Liu Q. et al. Identification ofMACCl as a novel prognostic marker in hepatocellular carcinoma.J Transl Med, 2011, 9: 166.
  • 7Zhang R, Shi H, Chen Z, et al. Effects of metastasis-associated in colon cancer 1 inhibition by small hairpin RNA on ovarian carcinoma OVCAR-3 cells.J Exp Clin Cancer Res, 2011,30: 83.
  • 8Chundong G, Uramoto H, Onitsuka T, et al. Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis. Anticancer Res, 2011, 31(4): 1141-1145.
  • 9吕煊.MACC1对前列腺癌体外侵袭转移能力的影响[M].武汉.华中科技大学.2011.
  • 10Eder JP, Vande Woude GF, Boerner SA, et al. Novel therapeutic inhibitors of the c-met signaling pathway in cancer. Clin Cancer Res,2009,15(7): 2207-2214.

共引文献67

同被引文献52

  • 1Denis MG, Vallee A, Theoleyre S. EGFR T790M resistance mutation in non small-cell lung carcinoma [J] . Clin Chim Acta, 2015, 444 ( 444 ) : 81-85.
  • 2Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefltinib [ J ] . N Engl J Med, 2005, 352 ( 8 ) : 786-792.
  • 3Shimamura T, Li D, Ji H, et al. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance[ J 1. Cancer Res, 2008, 68 ( 14 ) : 5827-5838.
  • 4Ma C, Wei S, Song Y. T790M and acquired resistance of EGFR TKI : a literature review of clinical reports [ J ] . J Thorac Dis, 2011, 3 ( 1 ) : 10-18.
  • 5Fujita Y, Suda K, Kimura H, et al. Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation [J] . J Thorac Oncol, 2012, 7 ( 11 ) : 1640-1644.
  • 6Su KY, Chen HY, Li KC, et al. Pretreatment epidermal growth factor receptor ( EGFR ) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer [ J ] . J Clin Oncol, 2012, 30 ( 4 ) : 433-440.
  • 7Suda K, Onozato R, Yatabe Y, et al. EGFR T790M mutation : adouble role in lung cancer cell survival? [ J ] . J Thorac Oncol, 2009, 4(1):1-4.
  • 8Iwama E, Takayama K, Harada T, et al. Highly sensitive and quantitative evaluation of the EGFR T790M mutation by nanofluidic digital PCR [ J ] . Oncotarget, 2015, 6 ( 24 ) : 20466-20473.
  • 9Ishii H, Azuma K, Sakai K, et al. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC : Con'elation with paired tumor samples [ J ] . Oncotarget, 2015, 6 ( 31 ) : 30850-30858.
  • 10Sequist LV, Wahman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors [ J ] . Sci Transl Med, 2011, 3 ( 75 ) : 75ra26.

引证文献2

二级引证文献4

解放军医学院学报
2015年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部